About IDS
IDS is headquartered in the UK, and has subsidiaries in the USA,
Germany, France, Denmark, Finland and Belgium, offering next day
delivery in all major territories. The markets of Spain, Italy,
Australia, Japan and elsewhere are serviced by a network of highly
qualified and experienced distributors.
The company enjoys a dominant position in the provision of immunoassay
kits for the determination of Vitamin D (for the more technical, both
25 Hydroxy- and 1,25 Dihydroxy- Vitamin D).
Their track record of delivering innovative new products, by de novo
or collaborative programmes with academia, or the judicious acquisition
of complementary products and/or companies, has given IDS the broadest
range of bone and skeletal biomarker kits available anywhere in the
world.
IDS meet the needs of its pharmaceutical and clinical customers by
providing a range of Research Use Only kits for researchers in drug
development and pre-clinical studies, and in offering fully-optimised
and validated 'human' kits for ensuing clinical studies, and ultimately
for use by the Clinical Chemist for routine IVD purposes.
The
increase in the aging population throughout the world has resulted in a
higher incidence of conditions such as osteoporosis, rheumatoid and
osteo- arthritis, renal and cardiovascular disease. The spiralling
socio-economic costs of fractures and other age-related morbidities are
driving the need for better tools to monitor health and diagnose
disease onset much earlier, and IDS intends to play a full part in
this.
IDS is a listed company, traded on the Alternative Investment Market (AIM; trading symbol IDH) of the London Stock Exchange.
To view IDS products list click here